Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $27.1000 (2.46%) ($26.2800 - $27.4100) on Fri. Mar. 16, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.47% (three month average) | RSI | 56 | Latest Price | $27.1000(2.46%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.4% a day on average for past five trading days. | Weekly Trend | ADMS advances 4.3% a week on average for past two weeks. | Market Behavior | Normal for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(24%) IBB(22%) QQQ(19%) ARKK(18%) IWM(18%) | Factors Impacting ADMS price | ADMS will decline at least -2.235% in a week (0% probabilities). VIXM(-12%) UNG(-10%) BNDX(-10%) UUP(-7%) TLT(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.235% (StdDev 4.47%) | Hourly BBV | 0 () | Intraday Trend | 2.3% | | | |
|
5 Day Moving Average | $27.12(-0.07%) | 10 Day Moving Average | $26.67(1.61%) | 20 Day Moving Average | $26.58(1.96%) | To recent high | -36.5% | To recent low | 11.2% | Market Cap | $766m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |